

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound:

- ~~-butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate;~~
- N,2-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- N,2-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- N,3-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- N,3-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- 2,6-di-*tert*-butyl-4-{2-[3-methyl-1-(methylamino)butyl]-1,3-thiazol-4-yl}phenol;
- [4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methylamine;
- 2,6-di-*tert*-butyl-4-{2-[(*IS*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
- 2,6-di-*tert*-butyl-4-{2-[(*IR*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
- N-{[4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methyl}-N-methylamine;
- N-methyl-N-{[4-(3,4,5-trimethoxyphenyl)-1,3-thiazol-2-yl]methyl}amine;
- ethyl N-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinate;
- N-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycine;
- 2,6-di-*tert*-butyl-4-{2-[(4-methoxypiperidin-1-yl)methyl]-1,3-thiazol-4-yl}phenol;
- ~~-N-methyl-N-[(*IS*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl]amine;~~
- ~~-N,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;~~
- N-methyl-N-[(*IS*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl]amine;
- 4-{2-[(*IR*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-{2-[(*IS*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-[2-(1-aminocyclopropyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- 4-{2-[(methylamino)methyl]-1,3-thiazol-4-yl}benzene-1,2-diol;
- ~~-N-methyl-N-[(*IR*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl]amine;~~

~~-(1R)-2-methyl-1-[4-(10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;~~

- *N*-methyl-*N*-{(*1R*)-2-methyl-1-[4-(10H-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl} amine;

- *N*²-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl} glycineamide;

- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}-*N*-(2-ethoxy-2-oxoethyl)glycinate;

- 4-(3,5-di-*tert*-butyl-4-methoxyphenyl)-2-(methoxymethyl)-1,3-thiazole;

~~-4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;~~

or salts or combinations thereof.

2. (Withdrawn) A compound according to claim 1, wherein the compound is butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate or a salt thereof.

3. (Currently Amended) A compound; ~~or salt according to claim 1, wherein the compound is~~ 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol or a salt thereof.

4. (Currently Amended) A medicament, comprising a compound:

~~-butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate;~~

- *N*,2-dimethyl-1-[4-(10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;

- *N*,2-dimethyl-1-[4-(10H-phenoxazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;

- *N*,3-dimethyl-1-[4-(10H-phenoxazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;

- *N*,3-dimethyl-1-[4-(10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;

- 2,6-di-*tert*-butyl-4-{2-[3-methyl-1-(methylamino)butyl]-1,3-thiazol-4-yl}phenol;

- [4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methylamine;

- 2,6-di-*tert*-butyl-4-{2-[(*1S*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;

- 2,6-di-*tert*-butyl-4-{2-[(*1R*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;

- *N*-{[4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methyl}-*N*-methylamine;

- *N*-methyl-*N*-{[4-(3,4,5-trimethoxyphenyl)-1,3-thiazol-2-yl]methyl} amine;

- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl} glycinate;

- *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl} glycine;

- 2,6-di-*tert*-butyl-4-{2-[(4-methoxypiperidin-1-yl)methyl]-1,3-thiazol-4-yl}phenol;
- ~~- *N*-methyl-*N*-{(1*S*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;~~
- ~~- *N*,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;~~
- *N*-methyl-*N*-{(1*S*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- 4-{2-[(1*R*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-{2-[(1*S*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-[2-(1-aminocyclopropyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- 4-{2-[(methylamino)methyl]-1,3-thiazol-4-yl}benzene-1,2-diol;
- ~~- *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;~~
- ~~- (1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;~~
- *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- *N*²-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinamide;
- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}-*N*-(2-ethoxy-2-oxoethyl)glycinate;
- 4-(3,5-di-*tert*-butyl-4-methoxyphenyl)-2-(methoxymethyl)-1,3-thiazole;
- ~~- 4-{2-(1-aminocyclopentyl)-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;~~

or pharmaceutically acceptable salts or combinations thereof.

5. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, at least one of the compounds or pharmaceutically acceptable salts of claim 4.

6. (Withdrawn) A method of treating disorders/pathologies selected from neurodegenerative diseases, pain, or epilepsy comprising administering a medicament to a patient, wherein the medicament comprises one of the compounds or pharmaceutically acceptable salts of claim 4.

7. (Withdrawn) The method of claim 6, wherein the disorders/pathologies treated are neurodegenerative diseases.

8. (Withdrawn) The method of claim 7, wherein the compound or pharmaceutically acceptable salt is 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol or pharmaceutically acceptable salts thereof.

9. (Withdrawn) The method of claim 6 comprising treating pain.

10. (Withdrawn) The method of claim 9, wherein the compound or pharmaceutically acceptable salt is butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate or pharmaceutically acceptable salts thereof.

11. (New) A medicament, comprising a compound:
4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol or pharmaceutically acceptable salts thereof.

12. (New) A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salts of claim 11.

13. (New) A compound:

- *N*-methyl-*N*-{(1*S*)-2-methyl-1-(4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;

- *N*,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;

- *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;

- (1*R*)-2-methyl-1-(4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;

or pharmaceutically acceptable salts or combinations thereof.

14. (New) A medicament, comprising a compound:

- *N*-methyl-*N*-{(1*S*)-2-methyl-1-(4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl)propyl} amine;
 - *N*,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl} amine;
 - (1*R*)-2-methyl-1-(4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- or pharmaceutically acceptable salts thereof.

15. (New) A pharmaceutical composition comprising, as an active ingredient, at least one of the compounds or pharmaceutically acceptable salts of claim 14.